Nirmatrelvir: From Discovery to Modern and Alternative Synthetic Approaches DOI Open Access
Michela Galli,

Francesco Migliano,

Valerio Fasano

et al.

Processes, Journal Year: 2024, Volume and Issue: 12(6), P. 1242 - 1242

Published: June 17, 2024

The global urgency in response to the COVID-19 pandemic has catalyzed extensive research into discovering efficacious antiviral compounds against SARS-CoV-2. Among these, Nirmatrelvir (PF-07321332) emerged as a promising candidate, exhibiting potent activity by targeting main protease of SARS-CoV-2, and been marketed combination with ritonavir first oral treatment for name PaxlovidTM. This review outlines synthetic approaches Nirmatrelvir, ranging from Pfizer’s original method newer, more sustainable strategies, such flow chemistry strategies multicomponent reactions. Each approach’s novelty contributions yield purification processes are highlighted. Additionally, synthesis key fragments comprising innovative optimization discussed.

Language: Английский

The Use of Nirmatrelvir-ritonavir in a Case of Breakthrough Long COVID DOI Open Access
Linda N. Geng, Hector Bonilla, Robert W. Shafer

et al.

Exploratory Research and Hypothesis in Medicine, Journal Year: 2023, Volume and Issue: 000(000), P. 394 - 396

Published: Jan. 13, 2023

Post-acute sequelae of SARS-CoV-2 (PASC) or long COVID is a major public health problem. The underlying mechanism(s) this disease remains unclear, and there lack effective therapies. We report case 47-year-old patient who experienced breakthrough acute COVID-19 with PASC after two doses vaccination, its symptom resolution following course the novel combination antiviral nirmatrelvir-ritonavir. One several leading hypotheses on pathogenesis persistent viral reservoir. This raises important questions potential role therapies in COVID, need for further research clinical trials field study.

Language: Английский

Citations

8
COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic DOI Creative Commons
Iwona Hus, Agnieszka Szymczyk,

Joanna Mańko

et al.

Biology, Journal Year: 2023, Volume and Issue: 12(4), P. 545 - 545

Published: April 3, 2023

The COVID-19 pandemic is undoubtedly the most difficult health challenge of 21st century with more than 600 million laboratory-confirmed SARS-CoV-2 infections and over 6.5 deaths worldwide. coronavirus contributed to rapid development mRNA vaccines, which, along new antiviral drugs, have been subject extensive research for many decades. Nevertheless, elderly, multi-morbid immunocompromised patients continue face a severe clinical course higher risk death from COVID-19, even now that in general population significantly reduced due introduction global vaccination strategies. In this paper, we present mechanisms increased susceptibility infectious complications evolution hematological malignancies, taking into account mutation virus vaccines drugs. We also current recommendations prophylactic therapeutic management malignancies.

Language: Английский

Citations

8
Curtailing virus-induced inflammation in respiratory infections: emerging strategies for therapeutic interventions DOI Creative Commons

Alexander A. Globenko,

Gennady V. Kuzin,

Anastasia V. Rydlovskaya

et al.

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: May 5, 2023

Acute respiratory viral infections (ARVI) are the most common illnesses worldwide. In some instances, mild cases of ARVI progress to hyperinflammatory responses, which damaging pulmonary tissue and requiring intensive care. Here we summarize available information on preclinical clinical effects XC221GI (1-[2-(1-methyl imidazole-4-yl)-ethyl]perhydroazin-2,6-dione), an oral drug with a favorable safety profile that has been tested in animal models influenza, syncytial virus, highly pathogenic coronavirus strains other acute upper infections. is capable controlling IFN-gamma-driven inflammation as it evident from suppression production soluble cytokines chemokines, including IL-6, IL-8, CXCL10, CXCL9 CXCL11 well decrease migration neutrophils into tissue. An excellent XC221GI, not metabolized by liver, its significant anti-inflammatory indicate utility this compound abating conversion ambulatory aggravated presentation require hospitalization. This especially useful when rapid molecular assays determining species impractical, or direct antiviral drugs available. Moreover, may be combined enhance their therapeutic effects.

Language: Английский

Citations

8
Using alternative SMILES representations to identify novel functional analogues in chemical similarity vector searches DOI Creative Commons
Clayton W. Kosonocky, Aaron L. Feller, Claus O. Wilke

et al.

Patterns, Journal Year: 2023, Volume and Issue: 4(12), P. 100865 - 100865

Published: Oct. 30, 2023

Language: Английский

Citations

7
Nirmatrelvir: From Discovery to Modern and Alternative Synthetic Approaches DOI Open Access
Michela Galli,

Francesco Migliano,

Valerio Fasano

et al.

Processes, Journal Year: 2024, Volume and Issue: 12(6), P. 1242 - 1242

Published: June 17, 2024

The global urgency in response to the COVID-19 pandemic has catalyzed extensive research into discovering efficacious antiviral compounds against SARS-CoV-2. Among these, Nirmatrelvir (PF-07321332) emerged as a promising candidate, exhibiting potent activity by targeting main protease of SARS-CoV-2, and been marketed combination with ritonavir first oral treatment for name PaxlovidTM. This review outlines synthetic approaches Nirmatrelvir, ranging from Pfizer’s original method newer, more sustainable strategies, such flow chemistry strategies multicomponent reactions. Each approach’s novelty contributions yield purification processes are highlighted. Additionally, synthesis key fragments comprising innovative optimization discussed.

Language: Английский

Citations

2